The six PANoptosis hub genes and their derived PRS show strong diagnostic potential, while integrated regulatory and druggability analyses nominate <i>CASP1, FAS, PSMB9</i> and <i>PRKACB</i> as promising biomarkers and therapeutic entry points for PANoptosis-centered interventions in DKD. Here, FAS is linked to diabetic kidney disease.